InterventionsHuman trial

Baseline Characteristics of Participants Who Achieved Normal BMI—Surmount-1 Three-Year Study Post Hoc Analysis

ADA Scientific Sessions 2025 Abstract

The paper

Reshmi Srinath, Naveed A. Sattar, Hui Wang,

Beverly L. Falcón, Luis-Emilio Garcia-Perez, Adam Stefański, Arian W. Plat,

New York

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Poster 1772-P

doi.org/10.2337/db25-1772-p

Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026